Aptadel Therapeutics Grant - ADEL-101 (Initial Award)

Aptadel Therapeutics Initial Grant

Funder: Little Warrior Foundation Inc (WI, US)
Amount: $500,000
Status: Awarded (announced March 31, 2025)
Geographic Scope: Spain (Barcelona)
Type: First international grant from LWF

Focus Areas

• Drug: ADEL-101 (aptamer-based drug conjugate - ApDC)
• Target: EWS::FLI1 fusion - primary driver of Ewing sarcoma
• Mechanism: Two-pronged therapeutic with homing mechanism and toxic payload
- Homing: RNA-based aptamer recognizing epHA2 (overexpressed on Ewing sarcoma cells) - Payload: siRNA designed to silence EWSR1::FLI1 (Type 1) fusion gene

Research Support

Funding supports key preclinical studies including:
• Testing different dosing strategies and combination regimens
• Evaluating in vivo efficacy of ADEL-101
• Generating data for Investigational New Drug (IND)-enabling discussions
• Bringing therapy closer to clinical trials

Contact Information

Little Warrior Foundation PO Box 2124 Brookfield, WI 53008-2124 info@littlewarrior.org EIN: 84-4322722